CEO – Sijme Zeilemaker
Over 10 years of experience in biotech companies in oncology, business development and investor relations. Building companies, pursuing industry leadership, pitching to pharma and investors.
COO & Founder – Gerben Zondag, PhD
Over 20 years of experience in biotech companies in operational and leadership roles. Strong entrepreneurial skills and scientific background in molecular biology.
CSO – Jeroen van Bergen, PhD
Cum laude PhD in tumor immunology, EMBO & VENI fellow, 25 years of experience in immunology with over 50 publications.
Ron Verweij, chairman
Healthcare & IT entrepreneur
Paul van der Horst, PhD
CBO Agomab; Head Corporate Development Galapagos
CEO PharmaFluidics; Solvay, bio.be
Scientific Advisory Board
Morten Nielsen, PhD
Professor Bioinformatics, Department of Health Technology, Technical University of Denmark / CEO of EIR Sciences.
Patrick Ott, MD, PhD
Clinical Director, Melanoma Center, Dana-Farber Cancer Institute / Associate Professor of Medicine, Harvard Medical School.
Kirk Trisler, PhD
Former SVP Manufacturing & Product Development at Gritstone bio.
John Trowsdale, PhD
Emeritus Professor of Immunology, University of Cambridge.
Prof. Ferry Ossendorp
Synthetic Vaccine Biology and head of the Tumor Immunology group, Leiden University Medical Center.